Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Atara Biotherapeutics Inc is a biotechnology business based in the US. Atara Biotherapeutics shares (ATRA) are listed on the NASDAQ and all prices are listed in US Dollars. Atara Biotherapeutics employs 578 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $15.25 |
|---|---|
| 52-week range | $11.81 - $21.85 |
| 50-day moving average | $16.48 |
| 200-day moving average | $15.19 |
| Wall St. target price | $33.57 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.62 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $15.25 from 2022-01-26
| 1 week (2022-01-21) | 9.01% |
|---|---|
| 1 month (2021-12-24) | N/A |
| 3 months (2021-10-28) | -2.49% |
| 6 months (2021-07-28) | 15.62% |
| 1 year (2021-01-28) | -19.74% |
|---|---|
| 2 years (2020-01-28) | 8.93% |
| 3 years (2019-01-28) | 34.45 |
| 5 years (2017-01-27) | 13.38% |
| Revenue TTM | $12.8 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -48.04% |
| Return on equity TTM | -98.81% |
| Profit margin | 0% |
| Book value | $3.51 |
| Market capitalisation | $1.4 billion |
TTM: trailing 12 months
We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Atara Biotherapeutics's shares have ranged in value from as little as $11.81 up to $21.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 1.8616. This would suggest that Atara Biotherapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Atara Biotherapeutics, Inc. , an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.